An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA)

The lack of new antibacterial drugs entering the market and their misuse have resulted in the emergence of drug-resistant bacteria, posing a major health crisis worldwide. In particular, meticillin-resistant Staphylococcus aureus (MRSA), a pathogen responsible for numerous human infections, has beco...

Full description

Saved in:
Bibliographic Details
Published in:Antibiotics (Basel) 2015-10, Vol.4 (4), p.424-434
Main Authors: Lau, Qiu Ying, Tan, Yoke Yan Fion, Goh, Vanessa Chai Yin, Lee, David Jing Qin, Ng, Fui Mee, Ong, Esther H Q, Hill, Jeffrey, Chia, Cheng San Brian
Format: Article
Language:English
Subjects:
drug library screen
drug repositioning
drug repurposing
MRSA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The lack of new antibacterial drugs entering the market and their misuse have resulted in the emergence of drug-resistant bacteria, posing a major health crisis worldwide. In particular, meticillin-resistant Staphylococcus aureus (MRSA), a pathogen responsible for numerous human infections, has become endemic in hospitals worldwide. Drug repurposing, the finding of new therapeutic indications for approved drugs, is deemed a plausible solution to accelerate drug discovery and development in this area. Towards this end, we screened 1163 drugs approved by the Food and Drug Administration (FDA) for bioactivities against MRSA in a 10 μM single-point assay. After excluding known antibiotics and antiseptics, six compounds were identified and their MICs were determined against a panel of clinical MRSA strains. A toxicity assay using human keratinocytes was also conducted to gauge their potential for repurposing as topical agents for treating MRSA skin infections.
ISSN:2079-6382
2079-6382
DOI:10.3390/antibiotics4040424